In communities like Marquette or Iron Mountain, driving to a weight loss specialist simply isnt a realistic option for most people
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
Similar content being viewed by others Background The Coronavirus disease 2019 (COVID-19) pandemic has led to long-term health implications for many individuals, particularly those with underlying chronic conditions [1, 2]
For instance, diets rich in fiber, particularly soluble fiber, can potentially enhance GLP-1 release
Plus, their soluble fiber slows down stomach emptying, keeping you feeling full for longer
Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
